Hepatitis B Therapeutics in Major Developed Industrial and Market studiess to 2021 - Increasing Number of Migrants from

"Hepatitis B Therapeutics in Major Developed Markets to 2021 - Increasing Number of Migrants from High-Prevalence Regions to Drive Market Growth" The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect.

Description-

Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. Approximately 350 million people worldwide are infected with chronic hepatitis B, which causes significant morbidity and mortality. Around 780,000 patients die from hepatitis B each year, of which 650,000 deaths are due to complications such as cirrhosis and liver cancer. Despite this, diagnosis and treatment rates are poor, stemming from its asymptomatic nature.

• The current hepatitis B market contains mainly nucleoside analog reverse transcriptase inhibitors, nucleotide analogs, and interferons.


• Will these drugs continue to dominate hepatitis B treatment?


• With 81 active pipeline molecules, most of the investigational drug candidates are small molecules and vaccines, comprising 64% of the pipeline.


• What are the most prominent small molecules and vaccines in the pipeline?


• Do the pipeline molecules offer advantages over commercially proven mechanisms?


• Analysis of clinical trials since 2006 has identified a high rate of attrition in hepatitis B products.


• How do failure rates vary by product stage of development, molecule type, and mechanism of action?


• How do other factors such as average trial duration and trial size influence the costs and risks associated with product development?


• Over the 2014